News | December 14, 2025
Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India
Subscribe To Our Newsletter & Stay Updated
